SENO Senorx (MM)

Law Offices of Howard G. Smith announces that it is investigating potential claims against the board of directors of SenoRx, Inc. (“SenoRx” or the “Company”) (NASDAQ:SENO) related to the Company’s agreement to be acquired by medical device manufacturer C. R. Bard, Inc. (“Bard”). The all-cash transaction is valued at approximately $200 million.

Under the terms of the definitive merger agreement entered into by the parties, SenoRx stockholders will receive $11.00 in cash for each share of the Company’s stock that they hold at the closing of the merger. The transaction is expected to close in the third quarter of 2010. Upon completion of the merger SenoRx will become part of Bard’s Peripheral Vascular division. The investigation concerns possible breaches of fiduciary duty and other violations of law related to approval of the transaction by the SenoRx board of directors.

If you own shares of SenoRx, if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, Toll Free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at http://www.howardsmithlaw.com.

Senorx (MM) (NASDAQ:SENO)
Historical Stock Chart
From Oct 2024 to Nov 2024

Senorx (MM) (NASDAQ:SENO)
Historical Stock Chart
From Nov 2023 to Nov 2024